Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cassava Sciences Inc (FLNA) vs Grab Holdings Ltd. (GRAB) Price & Performance

Cassava Sciences IncTrade
Grab Holdings Ltd.Trade

Price performance (Past 24H)

Key statistics

Cassava Sciences Inc vs Grab Holdings Ltd. — how do they compare? Cassava Sciences Inc trades at $0.97 (market cap $47.75M), while Grab Holdings Ltd. trades at $3.73 (market cap $14.97B). The key difference: Grab Holdings Ltd. is far larger — about 313.5× Cassava Sciences Inc's market cap, and Grab Holdings Ltd. is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.

FLNAGRAB
Market Cap
$47.75M$14.97B
Sector
HealthTechnology
52-Week High
$4.64$6.45
52-Week Low
$0.87$3.27
Enterprise Value
-$34.93M$10.70B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cassava Sciences Inc

FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.

Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.

Grab Holdings Ltd.

GRAB trades at $3.66, down 0.27% on the day, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $3.37B in 2025, with net income turning positive at $268M, reflecting improved profitability. The company raised its 2026 guidance, supported by growth in on-demand and financial services segments. Analyst sentiment is overwhelmingly positive, with 91.67% recommending Buy.

Outlook remains favorable due to sustained revenue growth and margin expansion, but risks include high valuation multiples and insider selling. The stock offers upside to the average price target of $5.86, though volatility from competitive pressures and macroeconomic headwinds warrants caution.

Returns comparison

Trailing returns across standard periods

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA

About Grab Holdings Ltd.

Grab Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops delivery management, mobility, financial services, and enterprise software solutions. Grab Holdings serves customers worldwide.

Read more on GRAB